DICE Therapeutics, Inc.

26 articles about DICE Therapeutics, Inc.

• 

  10 Multibillion-Dollar M&As That Closed Since July 2023

  2/21/2024

  After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.

• Lilly Announces Extension of Tender Offer to Acquire DICE

  7/25/2023

  Eli Lilly and Company announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of DICE Therapeutics, Inc., for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding.

• 

  9 Top M&As in the First Half of 2023

  6/28/2023

  Despite a challenging economic climate and gloomy forecast, 2023 has still notched some mega-deals for biopharmas. BioSpace highlights the biggest deals in the industry this year.

• Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

  6/20/2023

  Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.

• 

  Lilly Aims to Boost Immuno Business with $2.4B DICE Buy

  6/20/2023

  Eli Lilly stands to gain access to DICE Therapeutics’ DELSCAPE platform, which enables the design of orally available molecules for autoimmune and inflammatory diseases.

• DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023

  6/13/2023

  DICE Therapeutics, Inc. announced that management will host a research & development day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY.

• DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

  5/11/2023

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.

• DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference

  5/3/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.

• DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

  3/23/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.

• DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

  3/15/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.

• DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

  3/1/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA.

• DICE Therapeutics to Participate at Upcoming Investor Conferences - February 08, 2023

  2/8/2023

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced management will participate at the following investor conferences.

• DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.

• DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

  11/9/2022

  DICE Therapeutics, Inc. (Nasdaq: DICE) today reported financial results and business highlights for the third quarter ended September 30, 2022.

• DICE Therapeutics to Present at Upcoming November 2022 Investor Conferences

  11/3/2022

  DICE Therapeutics, Inc. announced that management will present at the following investor conferences.

• DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

  8/11/2022

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, reported financial results and business highlights for the second quarter ended June 30, 2022.

• DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

  7/21/2022

  DICE Therapeutics, Inc. (Nasdaq: DICE), today announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients.

• DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

  6/1/2022

  DICE Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.

• DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

  5/12/2022

  DICE Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.

• DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

  5/3/2022

  DICE Therapeutics, Inc. today announced that management will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 1:20 p.m. PT / 4:20 p.m. ET.